is a common cause of respiratory infections, with the peak season typically being fall through winter. In most people, the infection triggers mild cold symptoms like runny nose, coughs, and sneezing. But in very young children as well as older and immunocompromised adults, it has a higher risk of causing more serious complications that can be life-threatening, such as pneumonia and bronchiolitis .
“Today’s results represent an important step forward in preventing lower respiratory disease due to RSV in adults 60 years of age and older,” said Moderna CEO Stéphane Bancel in a
Anyone working on a Common Cold Vaccine or better Antiviral?
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna says RSV vaccine 84% effective at preventing symptoms in older adultsModerna Inc said on Tuesday that its experimental messenger RNA vaccine for respiratory syncytial virus (RSV) was 83.7% effective in a late-stage trial at preventing at least two symptoms, such as cough and fever, in adults aged 60 and older. RSV aşısı.,! Moderna yeni bir yalana daha imza attı..! What are the side affects? Generally safe? What does that mean? 'The RSV vaccine market could be worth more than $10 billion globally, half of which would come from the United States, according to Cowen analyst Tyler Van Buren.' It's not about RSV, it's about $$$$$$$$$
Source: Reuters - 🏆 2. / 97 Read more »
Moderna is the latest company to produce a promising RSV vaccineThe experimental respiratory syncytial virus vaccine prevented most infections in older adults in a Phase 3 clinical trial Amazing news I have 5 Moderna Covid vaccines. I'll get this one too as soon as I can.
Source: MarketWatch - 🏆 3. / 97 Read more »